Press releases

Oncopeptides publishes the 2025 Annual Report

Annual General Meeting in Oncopeptides

Preclinical data on novel NK-Cell engager to be presented at the AACR Annual Meeting 2026

Number of shares and votes in Oncopeptides

Outcome in Oncopeptides’ rights issue

Oncopeptides initiates MARINA study to strengthen real-world evidence for Pepaxti in Germany

European Journal of Haematology: Real-World Data reinforces Pepaxti’s role in treatment sequencing for multiple myeloma

Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma

Oncopeptides publishes disclosure document regarding rights issue

Oncopeptides publishes year-end report 2025

Oncopeptides carries out a rights issue of approximately SEK 200 million

Invitation to presentation of the year-end report 2025